Results 51 to 60 of about 10,116 (213)

Clinical Recovery and Circulating Botulinum Toxin Type F in Adult Patient

Emerging Infectious Diseases, 2009
A 56-year-old woman in Helena, Montana, USA, who showed clinical signs of paralysis, received antitoxins to botulinum toxins A, B, and E within 24 hours; nevertheless, symptoms progressed to complete quadriplegia. On day 8, she began moving spontaneously,
Jeremy Sobel, Tracy Dill, Christina L. Kirkpatrick, Laurel Riek, Patrick Luedtke, Todd A. Damrow   +5 more
doaj   +1 more source

Hazard analysis and possibilities for preventing botulism originating from meat products [PDF]

Veterinarski Glasnik, 2008
The paper presents the more important data on the bacteria Clostridium botulinum, the appearance of botulism, hazard analysis and the possibilities for preventing botulism.
Vasilev Dragan, Vuković Ilija
doaj   +1 more source

Recombinant versus native botulinum neurotoxin type A: structural and pharmacodynamic comparison. [PDF]

Acta Crystallogr F Struct Biol Commun
For the first time, the recombinant core botulinum neurotoxin type A (BoNT/A) expressed in Escherichia coli and nicked in vitro is shown to be structurally identical to native BoNT/A from Clostridium botulinum, enabling direct activity comparison between the recombinant product and the native toxin.Botulinum neurotoxins (BoNTs) are highly potent ...
Yao Z, Xu L, Lu Y, Gong H, Sun X, Zhao Y, Chen J, Yang L, Chen Q, Yang W.   +9 more
europepmc   +2 more sources

Two pediatric type II achalasia cases complicated by candidal and eosinophilic esophagitis: Successful peroral endoscopic myotomy treatment

JPGN Reports, EarlyView.
Abstract Achalasia is a rare esophageal motility disorder in children, often leading to delayed diagnosis. We report the first two pediatric cases treated with peroral endoscopic myotomy (POEM) at our center, both classified as type II achalasia and complicated by mucosal disease. A 15‐year‐old girl presented with progressive dysphagia and weight loss,
Fabio Rotondo, Antonio Marseglia, Anna Locatelli, Dalila Tedeschi, Marco Gentile, Francesco Perri, Maria Rosa Pastore, Massimo Pettoello Mantovani   +7 more
wiley   +1 more source

Th2/Th17 Inflammation: Pathogenic Drivers and Therapeutic Targets in Darier and Hailey‐Hailey Diseases

JEADV Clinical Practice, EarlyView.
Skin samples of Hailey‐Hailey and Darier diseases were analyzed for inflammatory and barrier markers using indirect immunofluorescence and transcriptomic techniques. A mixed Th2/Th17 inflammatory pattern and altered expression of barrier markers were observed.
Ella Glodjajic, Darko Stojkov, Joanna Boros‐Majewska, Jeremy Di Domizio, Michel Gilliet, Christoph Schlapbach, Timothée Fettrelet, Luca Borradori, Hans‐Uwe Simon, Dagmar Simon, Susanne Radonjic‐Hoesli   +10 more
wiley   +1 more source

Mechanisms of Botulinum Toxin Type A Action on Pain [PDF]

Toxins, 2019
Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic
Matak, Ivica, Bölcskei, Kata, Bach-Rojecky, Lidija, Helyes, Zsuzsanna   +3 more
openaire   +6 more sources

Cervical Inlet Patches in R‐CPD: An Unrecognized Predictor of Treatment Failure

The Laryngoscope, EarlyView.
This retrospective cohort study identified cervical inlet patches (CIP) in 19.8% of patients undergoing cricopharyngeal botulinum toxin injection for R‐CPD. CIP presence and increasing age independently predicted failure to sustain a long‐term treatment response, suggesting that CIP may be an underrecognized factor in R‐CPD treatment durability ...
Andrew Geoffrey Tritter, Nabeeha Hasan, Jered Wilson   +2 more
wiley   +1 more source

Supraglottic Botulinum Toxin Injection Improves Symptoms of Laryngeal Sensory Dysfunction

The Laryngoscope, EarlyView.
In this retrospective cohort of 80 patients with refractory laryngeal sensory symptoms, supraglottic botulinum toxin type A significantly improved Laryngeal Hypersensitivity Questionnaire, Reflux Symptom Index, and Cough Severity Index scores at a mean of 5.2 weeks, while Voice Handicap Index‐10 scores remained unchanged.
Daniel Novakovic, Katrina Sandham, Thomas Emslie Stewart, James Jordan Johnston   +3 more
wiley   +1 more source

Impact of Frailty on Surgical Outcomes in Patients Treated for Cricopharyngeus Muscle Dysfunction

The Laryngoscope, EarlyView.
ABSTRACT Objective To investigate the relationship between frailty status and surgical outcomes in patients undergoing procedures for cricopharyngeus muscle dysfunction (CPMD). Methods Retrospective chart review of all patients who underwent upper esophageal sphincter (UES) interventions at a tertiary dysphagia center.
Jessa Letargo, Ramey Kharfan, Charmaine Szalay‐Anderson, Derrick R. Randall   +3 more
wiley   +1 more source

Botulinum toxin type A on cutaneous flap viability in diabetic and tobacco-exposed rats [PDF]

Acta Cirúrgica Brasileira, 2015
PURPOSE:To investigate the effect of Botulinum toxin A (BoNTA) on skin flap viability in healthy, tobacco-exposed and diabetic rats.METHODS: Ninety male Wistar rats (250-300g) were randomly divided into six groups: control+saline (C1), control+BoNTA (C2),
Cristina Pires Camargo, Alfredo Luiz Jacomo, Cláudia Naves Battlehner, Miriam Lemos, Paulo Hilário Saldiva, Milton Arruda Martins, Alexandre Mendonça Munhoz, Rolf Gemperli   +7 more
doaj   +1 more source